Merck KGaA (OTCMKTS:MKKGY) Cut to “Strong Sell” at Zacks Research

Merck KGaA (OTCMKTS:MKKGY) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report issued on Monday, Zacks reports.

Several other research firms have also recently commented on MKKGY. UBS Group cut Merck KGaA from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 20th. HSBC raised Merck KGaA to a “hold” rating in a report on Monday, July 6th. Five equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Reduce”.

Merck KGaA Trading Down 0.3%

Shares of MKKGY stock opened at $30.89 on Monday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.09 and a current ratio of 1.69. Merck KGaA has a 52-week low of $23.73 and a 52-week high of $34.19. The company has a market capitalization of $19.96 billion, a PE ratio of 15.97, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. The business’s fifty day moving average is $31.51 and its 200 day moving average is $30.23.

Merck KGaA Company Profile

Merck KGaA is a Germany-based science and technology company headquartered in Darmstadt. Founded in 1668, it is one of the world’s oldest pharmaceutical and chemical businesses. The company operates independently from Merck & Co, Inc, the U.S.-based company that uses the Merck name in the United States and Canada.

Merck KGaA operates through three primary business sectors: Life Science, Healthcare and Electronics. Its Life Science business supplies laboratory products, research tools, analytical technologies and bioprocessing solutions used by pharmaceutical and biotechnology companies, academic institutions and industrial laboratories.